We are live on ! Find out more
DYAI icon

Dyadic International

0.3108 USD
-0.0093
2.91%
At close Updated Nov 19, 4:00 PM EST
Pre-market
After hours
0.2920
-0.0188
6.05%
1 day
-2.91%
5 days
-11.2%
1 month
-18.4%
3 months
-57.94%
6 months
-56.89%
Year to date
-66.93%
1 year
-66.52%
5 years
-91.95%
10 years
-90.86%
 

About: Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Employees: 5

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
The Motley Fool
6 days ago
Dyadic: 3 Key Takeaways for Long-Term Investors
Third-quarter revenue decreased 61% year over year to $449,000. Gates-funded antibody programs achieved yields of 12.1 grams per liter.
Dyadic: 3 Key Takeaways for Long-Term Investors
Neutral
Seeking Alpha
7 days ago
Dyadic International, Inc. (DYAI) Q3 2026 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q3 2026 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q3 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
7 days ago
Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments
Advances Commercialization, Expands Strategic Partnerships and Accelerates Biopharmaceutical Platform Validation Dyadic to host earnings call on November 12, 2026, at 5:00 p.m. ET JUPITER, Fla.
Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments
Neutral
GlobeNewsWire
8 days ago
Dyadic's C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations
JUPITER, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, today announced that the Gates Medical Research Institute has initiated preclinical animal studies comparing monoclonal antibodies (mAbs) against respiratory syncytial virus (RSV) and malaria, produced using Dyadic's proprietary C1 protein production platform, with their respective mammalian-cell (CHO)-produced counterparts.
Dyadic's C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations
Neutral
GlobeNewsWire
10 days ago
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Al
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.
Neutral
GlobeNewsWire
20 days ago
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
JUPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended September 30, 2026 and host a corporate update conference call on Thursday, November 12, 2026.
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
Neutral
Seeking Alpha
2 months ago
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
Neutral
GlobeNewsWire
3 months ago
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants to the same investor.
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
Neutral
Seeking Alpha
3 months ago
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion.
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Price charts implemented using Lightweight Charts™